ClearPoint Neuro (Nasdaq:CLPT) - Hisse Senedi Fiyatı, Haberler ve Analizler

CLPT Stoklara Genel Bakış

ClearPoint Neuro, Inc. öncelikle Amerika Birleşik Devletleri'nde bir tıbbi cihaz şirketi olarak faaliyet göstermektedir.

Şirket hakkında

CLPT temel anali̇z
Kar Tanesi Skoru
Değerleme	0/6
Gelecekteki Büyüme	2/6
Geçmiş Performans	0/6
Finansal Sağlık	5/6
Temettüler	0/6

Ödüller

Revenue is forecast to grow 26.47% per year

Risk Analizi

Currently unprofitable and not forecast to become profitable over the next 3 years

Shareholders have been diluted in the past year

Volatile share price over the past 3 months compared to the US market

ClearPoint Neuro, Inc. Rakipler

Tactile Systems Technology

NasdaqGM:TCMD

US$352.1m

Paragon 28

NYSE:FNA

US$469.5m

Zynex

NasdaqGS:ZYXI

US$279.0m

Pulmonx

NasdaqGS:LUNG

US$247.6m

Fiyat Geçmişi ve Performans

için tüm zamanların en yüksek seviyelerinin, değişikliklerin ve fiyat düşüşlerinin özeti ClearPoint Neuro
Tarihsel hisse senedi fiyatları
Güncel Hisse Fiyatı	US$12.89
52 Haftanın En Yüksek Seviyesi	US$14.13
52 Haftanın En Düşük Seviyesi	US$4.05
Beta	1.11
11 Aylık Değişim	14.99%
3 Aylık Değişim	93.25%
1 Yıllık Değişim	114.48%
33 Yıllık Değişim	-30.36%
5 Yıllık Değişim	220.65%
Halka arzdan bu yana değişim	-57.03%

Son Haberler & Güncellemeler

Investors Appear Satisfied With ClearPoint Neuro, Inc.'s (NASDAQ:CLPT) Prospects As Shares Rocket 28%

Sep 14

Is ClearPoint Neuro (NASDAQ:CLPT) Weighed On By Its Debt Load?

Aug 16

Recent updates

Investors Appear Satisfied With ClearPoint Neuro, Inc.'s (NASDAQ:CLPT) Prospects As Shares Rocket 28%

Sep 14

Is ClearPoint Neuro (NASDAQ:CLPT) Weighed On By Its Debt Load?

Aug 16

Investors Appear Satisfied With ClearPoint Neuro, Inc.'s (NASDAQ:CLPT) Prospects As Shares Rocket 26%

Jul 11

ClearPoint Neuro, Inc. (NASDAQ:CLPT) Just Reported First-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?

May 09

ClearPoint Neuro: Macro-Induced Multiple Compression

Apr 25

Are ClearPoint Neuro, Inc. (NASDAQ:CLPT) Investors Paying Above The Intrinsic Value?

Apr 19

Analysts Have Made A Financial Statement On ClearPoint Neuro, Inc.'s (NASDAQ:CLPT) Yearly Report

Mar 15

Should You Investigate ClearPoint Neuro, Inc. (NASDAQ:CLPT) At US$6.18?

Jan 04

Does ClearPoint Neuro (NASDAQ:CLPT) Have A Healthy Balance Sheet?

Dec 06

Is There An Opportunity With ClearPoint Neuro, Inc.'s (NASDAQ:CLPT) 41% Undervaluation?

Nov 06

Hissedar Getirileri

	CLPT	US Medical Equipment	US Pazar
7D	-2.0%	0.2%	-1.6%
1Y	114.5%	25.8%	30.8%

Getiri vs. Endüstri: CLPT exceeded the US Medical Equipment industry which returned 25.8% over the past year.

Getiri vs Piyasa: CLPT exceeded the US Market which returned 30.8% over the past year.

Fiyat Oynaklığı

Is CLPT's price volatile compared to industry and market?
CLPT volatility
CLPT Average Weekly Movement	14.4%
Medical Equipment Industry Average Movement	8.0%
Market Average Movement	6.0%
10% most volatile stocks in US Market	14.9%
10% least volatile stocks in US Market	2.9%

İstikrarlı Hisse Senedi Fiyatı: CLPT's share price has been volatile over the past 3 months compared to the US market.

Zaman İçindeki Volatilite: CLPT's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of US stocks.

Şirket Hakkında

Kuruldu	Çalışanlar	CEO	Web sitesi
1998	107	Joe Burnett	www.clearpointneuro.com

ClearPoint Neuro, Inc. öncelikle Amerika Birleşik Devletleri'nde bir tıbbi cihaz şirketi olarak faaliyet göstermektedir. Manyetik rezonans görüntüleme rehberliğinde beyinde minimal invaziv cerrahi prosedürler gerçekleştirmeye yönelik platformlar geliştirmekte ve ticarileştirmektedir. Şirket, derin beyin stimülasyon elektrotlarının, biyopsi iğnelerinin ve lazer kateterlerinin yerleştirilmesi ve ilaçların beyne infüzyonu için entegre bir sistem olan ClearPoint sistemini sunmaktadır.

ClearPoint Neuro, Inc. Temel Bilgiler Özeti

ClearPoint Neuro'un kazançları ve gelirleri piyasa değeriyle nasıl karşılaştırılır?
CLPT temel i̇stati̇sti̇kler
Piyasa değeri	US$355.71m
Kazançlar(TTM)	-US$17.98m
Gelir(TTM)	US$28.07m

12.7x

P/S Oranı

-19.8x

F/K Oranı

CLPT aşırı değerli mi?

Gerçeğe Uygun Değer ve değerleme analizine bakınız

Kazanç ve Gelir

En son kazanç raporundan temel karlılık istatistikleri (TTM)
CLPT gelir tablosu (TTM)
Gelir	US$28.07m
Gelir Maliyeti	US$11.27m
Brüt Kâr	US$16.80m
Diğer Giderler	US$34.78m
Kazançlar	-US$17.98m

Son Raporlanan Kazançlar

Jun 30, 2024

Sonraki Kazanç Tarihi

Nov 07, 2024

Hisse başına kazanç (EPS)	-0.65
Brüt Marj	59.85%
Net Kâr Marjı	-64.06%
Borç/Özkaynak Oranı	31.1%

CLPT uzun vadede nasıl bir performans gösterdi?

Geçmiş performansı ve karşılaştırmayı görün

CLPT Stoklara Genel Bakış

Ödüller

Risk Analizi

ClearPoint Neuro, Inc. Rakipler

NasdaqGM:TCMD

US$352.1m

NYSE:FNA

US$469.5m

NasdaqGS:ZYXI

US$279.0m

NasdaqGS:LUNG

US$247.6m

Fiyat Geçmişi ve Performans

Son Haberler & Güncellemeler

ClearPoint Neuro, Inc. to Report Q3, 2024 Results on Nov 07, 2024

Investors Appear Satisfied With ClearPoint Neuro, Inc.'s (NASDAQ:CLPT) Prospects As Shares Rocket 28%

Price target increased by 18% to US$11.83

Is ClearPoint Neuro (NASDAQ:CLPT) Weighed On By Its Debt Load?

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

New minor risk - Share price stability

Recent updates

ClearPoint Neuro, Inc. to Report Q3, 2024 Results on Nov 07, 2024

Investors Appear Satisfied With ClearPoint Neuro, Inc.'s (NASDAQ:CLPT) Prospects As Shares Rocket 28%

Price target increased by 18% to US$11.83

Is ClearPoint Neuro (NASDAQ:CLPT) Weighed On By Its Debt Load?

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

New minor risk - Share price stability

ClearPoint Neuro, Inc. Raises Revenue Guidance for the Year 2024

Insufficient new directors

ClearPoint Neuro, Inc. to Report Q2, 2024 Results on Aug 07, 2024

Investors Appear Satisfied With ClearPoint Neuro, Inc.'s (NASDAQ:CLPT) Prospects As Shares Rocket 26%

ClearPoint Neuro, Inc.(NasdaqCM:CLPT) dropped from Russell Small Cap Completeness Index

ClearPoint Neuro, Inc. Initiates Its Full Market Release of the Smartframe

Consensus EPS estimates upgraded to US$0.66 loss

ClearPoint Neuro, Inc. (NASDAQ:CLPT) Just Reported First-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

ClearPoint Neuro, Inc. Announces FDA Clearance of Prism Bone Anchor Accessory

ClearPoint Neuro, Inc. Announces Initiation of Limited Market Release for the SmartFrame OR™ Stereotactic System

ClearPoint Neuro: Macro-Induced Multiple Compression

ClearPoint Neuro, Inc. to Report Q1, 2024 Results on May 07, 2024

Are ClearPoint Neuro, Inc. (NASDAQ:CLPT) Investors Paying Above The Intrinsic Value?

ClearPoint Neuro, Inc., Annual General Meeting, May 15, 2024

ClearPoint Neuro, Inc. Reaffirms Revenue Guidance for the Year 2024

Analysts Have Made A Financial Statement On ClearPoint Neuro, Inc.'s (NASDAQ:CLPT) Yearly Report

Full year 2023 earnings: EPS and revenues exceed analyst expectations

ClearPoint Neuro, Inc. Announces Preclinical Results of an in Vivo Validation Study Have Been Published in the Journal of Neurosurgery

President exercised options and sold US$69k worth of stock

New minor risk - Shareholder dilution

ClearPoint Neuro, Inc. to Report Q4, 2023 Results on Mar 12, 2024

ClearPoint Neuro, Inc. has completed a Follow-on Equity Offering in the amount of $15.000011 million.

ClearPoint Neuro, Inc. has filed a Follow-on Equity Offering.

ClearPoint Neuro, Inc. Announces FDA Clearance and First-In-Human Cases Performed with the New 2.2 Software Version and the Integrated Maestro Brain Model

Now 21% undervalued

Clearpoint Neuro Receives 510(K) Clearance for Smartframe or Stereotactic System

ClearPoint Neuro, Inc. Provides Revenue Guidance for the Full Year 2024

Should You Investigate ClearPoint Neuro, Inc. (NASDAQ:CLPT) At US$6.18?

Does ClearPoint Neuro (NASDAQ:CLPT) Have A Healthy Balance Sheet?

ClearPoint Neuro, Inc. Provides Earnings Guidance for the Year 2023

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Is There An Opportunity With ClearPoint Neuro, Inc.'s (NASDAQ:CLPT) 41% Undervaluation?

ClearPoint Neuro, Inc. to Report Q3, 2023 Results on Nov 09, 2023

Is ClearPoint Neuro (NASDAQ:CLPT) Using Debt In A Risky Way?

Consensus EPS estimates fall by 36%

ClearPoint Neuro, Inc. Reaffirms Its Revenue Guidance for Full Year 2023

Second quarter 2023 earnings: EPS misses analyst expectations

ClearPoint Neuro, Inc. to Report Q2, 2023 Results on Aug 08, 2023

Consensus EPS estimates fall by 13%

ClearPoint Neuro, Inc. Reaffirms Revenue Guidance for the Year 2023

Price target increased by 19% to US$22.00

ClearPoint Neuro, Inc. (NASDAQ:CLPT) Looks Just Right With A 40% Price Jump

Full year 2022 earnings: EPS exceeds analyst expectations

ClearPoint Neuro, Inc. to Report Q4, 2022 Results on Mar 01, 2023

ClearPoint Neuro, Inc. Provides Revenue Guidance for the Year 2023

Does ClearPoint Neuro (NASDAQ:CLPT) Have A Healthy Balance Sheet?

ClearPoint Neuro, Inc. Announces First Patient Enrolled in Glioblastoma Trial Using Clearpoint Prism Neuro Laser Therapy System At Skåne University Hospital in Sweden

Price target increased to US$20.25

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

ClearPoint Neuro, Inc. Reaffirms Revenue Guidance for the Year 2022

ClearPoint Neuro, Inc. to Report Q3, 2022 Results on Nov 08, 2022

ClearPoint Neuro, Inc. Announces FDA Clearance for ClearPoint Prism™ Neuro Laser Therapy System